A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH

Trial Profile

A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs Sapacitabine (Primary) ; Cyclophosphamide; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 27 Jun 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2019.
    • 09 Nov 2015 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top